5-FU did not uniformly suppress translation in HCT116 cells. At 10 or 50 µM for 24–48 h, IGF-1R mRNA association with heavy polysomes was maintained while actin/GAPDH association decreased. IGF-1R protein abundance also increased after 10 µM exposure. These findings show a selective cellular response during treatment rather than complete loss of translational capacity. [2]
Cellular thymidylate-synthase activity under fluoropyrimidine exposure
Cell-based study · SW480 colon adenocarcinoma and HeLa S3 cervical adenocarcinoma cells [1]
5-FU inhibited cellular TS activity less potently than FdUrd or FUrd under the same assay conditions. This is a cellular activity assay, not direct binding or a purified-enzyme potency measurement.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration series shown in Figure 6B; individual treatment points not transcribed
- Exposure duration
- 1 h drug pretreatment followed by 90 min tracer incubation
- Method
- Cellular TS activity measured by release of tritiated water from [5-3H]deoxyuridine, relative to untreated cells
- Reported limits
- Vehicle and full numerical dose series are not specified in the extracted record; no exact IC50 is assigned.
Methods and source locations
Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: FU
Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.
Figure 6B; Methods: TS assay; Results final subsection
Relative inhibition of cellular TS activity: Radiotracer TS assay; activity normalized to untreated samples — Figure 6B; Results final subsection
Nucleoside and nucleotide rescue of 5-FU cytotoxicity
Cell-based study · SW480 and HeLa S3 cells [1]
Uridine and UMP partially reversed 5-FU-associated loss of MTT signal, whereas deoxyuridine and thymidine did not reverse it. dTMP gave a limited rescue only at much higher concentrations than UMP. The response differed from FdUrd and supports an RNA-related component under these conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 6D: FU 15 µM (SW480) or 50 µM (HeLa); Figure 6E: FU 50 µM in both lines; increasing rescue-agent concentrations shown in the panels
- Exposure duration
- Four days, concurrent drug and rescue-agent exposure
- Method
- MTT survival assay compared with untreated cells
- Co-treatment
- Concurrent uridine, deoxyuridine or thymidine (6D), or UMP, dUMP or dTMP (6E). FdUrd and FUrd are separately tested comparator drugs.
- Reported limits
- Vehicle and individual rescue-agent dose points are not transcribed; no absolute survival percentage or rescue EC50 is assigned.
Methods and source locations
Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: FU
Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.
Figure 6D-E; Results final subsection; Methods: Survival assays after drug exposure
Rescue of 5-FU-associated cytotoxicity: MTT after four days; survival data reported as mean ± SD of at least two parallel measurements — Figure 6D-E and caption; Results final subsection
5-FU incorporation into mature ribosomal RNA
Cell-based study · HCT116 concentration series; HCT116, HT29, SW480, ISRECO-1, MDA-MB-231, BT20, Panc1 and MiaPaCa cellular panel [2]
LC-HRMS detected 5-fluorouridine in mature ribosomal RNA after 5-FU exposure. Gel-purified rRNA and ribosomal-subunit purification controls support assignment to rRNA rather than contaminating nonribosomal RNA.
Literature-Reported Treatment Conditions
- Treatment concentration
- HCT116: 5–100 µM 5-FU; cellular panel: 10 µM 5-FU
- Exposure duration
- 24 h
- Method
- LC-HRMS measurement of 5-FUrd in purified ribosomal RNA; untreated controls
- Vehicle
- Stock diluted in DMEM
- Reported limits
- Clinical stock formulation/excipients and product catalogue number are not specified in the cited Methods. Exact bar values are not estimated.
Methods and source locations
Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: 5-FU
Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.
Figure 2b-c; Supplementary Figure 3a-c; Results: 5-FU incorporates into ribosomes; relevant purification and LC-HRMS Methods
5-FUrd content of HCT116 ribosomes: LC-HRMS; main Figure 2b: mean ± SD of independent experiments, n = 3; range is stated in Results, not digitized — Figure 2b and Results: 5-FU incorporates into ribosomes
5-FUrd in rRNA across tested cell lines: LC-HRMS; Figure 2c mean ± SD, n = 3 independent experiments; gel purification controls n = 3; subunit-purification comparison n = 2 — Figure 2c and caption; Supplementary Figure 3a-c
Maintenance of IGF-1R translation during 5-FU treatment
Cell-based study · HCT116 colorectal cancer cells [2]
IGF-1R mRNA association with heavy polysomes was maintained while actin and GAPDH association decreased. IGF-1R protein abundance increased relative to untreated samples. These observations limit any claim that 5-FU uniformly blocks translation.
Literature-Reported Treatment Conditions
- Treatment concentration
- Polysome/qPCR: 10 or 50 µM 5-FU; protein immunoblot: 10 µM 5-FU
- Exposure duration
- 24 or 48 h
- Method
- Heavy-polysome versus cytoplasmic mRNA quantification; immunoblot using equivalent cell numbers and untreated controls
- Vehicle
- Stock diluted in DMEM
- Reported limits
- No exact effect size is inferred from bars. Protein analysis has only n = 2 independent experiments.
Methods and source locations
Compound reported in the paper: 5-Fluorouracil; Compound label in the paper: 5-FU
Molecular 5-FU evidence; no equivalence of supplier formulation, excipients, purity or Adooq lots is established.
Figure 4a-c; Supplementary Figure 6; Results: IGF-1R promotes 5-FU drug tolerance; Methods: Preparation of mRNA-associated polysomes; Quantitative RT-PCR; Western Blot
Heavy-polysome/cytoplasmic mRNA ratio: qRT-PCR of fractions; n = 3 independent experiments, biological samples measured in duplicate, mean ± SD — Figure 4a and caption; Supplementary Figure 6
IGF-1R protein abundance relative to untreated cells: Western blot; equivalent cell numbers loaded; mean ± SD of n = 2 independent experiments — Figure 4b-c and caption